Abstract
Neurons and neuroendocrine cells store nucleotides in vesicles and release them upon stimulation, leading to intercellular purinergic signaling. The molecular machinery responsible for the vesicular storage of nucleotides was a long standing enigma, however, recently the transporter involving in the process was identified. This article summarizes the history of vesicular storage of nucleotides and the identification of the vesicular nucleotide transporter (VNUT) responsible for the process. The significance of VNUT as a drug target to control purinergic chemical transmission is also discussed.
Keywords: Vesicular nucleotide transporter, secretory granules, synaptic vesicles, ATP, ADP, purinergic chemical transmission, drug target.
Current Pharmaceutical Design
Title:Vesicular Nucleotide Transport: A Brief History and the Vesicular Nucleotide Transporter as a Target for Drug Development
Volume: 20 Issue: 16
Author(s): Miki Hiasa, Natsuko Togawa and Yoshinori Moriyama
Affiliation:
Keywords: Vesicular nucleotide transporter, secretory granules, synaptic vesicles, ATP, ADP, purinergic chemical transmission, drug target.
Abstract: Neurons and neuroendocrine cells store nucleotides in vesicles and release them upon stimulation, leading to intercellular purinergic signaling. The molecular machinery responsible for the vesicular storage of nucleotides was a long standing enigma, however, recently the transporter involving in the process was identified. This article summarizes the history of vesicular storage of nucleotides and the identification of the vesicular nucleotide transporter (VNUT) responsible for the process. The significance of VNUT as a drug target to control purinergic chemical transmission is also discussed.
Export Options
About this article
Cite this article as:
Hiasa Miki, Togawa Natsuko and Moriyama Yoshinori, Vesicular Nucleotide Transport: A Brief History and the Vesicular Nucleotide Transporter as a Target for Drug Development, Current Pharmaceutical Design 2014; 20 (16) . https://dx.doi.org/10.2174/13816128113199990574
DOI https://dx.doi.org/10.2174/13816128113199990574 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Epigenetic Mechanisms and Kidney Diseases
Current Medicinal Chemistry Therapeutic Strategies for Huntingtons Disease: From the Bench to the Clinic
Current Psychopharmacology The Clinical Genetics of Psoriasis
Current Genomics Atherosclerotic Plaque Detection by Multi-detector Computed Tomography
Current Cardiology Reviews Therapeutic Proteins: A to Z
Protein & Peptide Letters Editorial [Hot Topic: Current Approaches to the Treatment of Diabetes (Guest Editor: Stephen L. Gwaltney II)]
Current Topics in Medicinal Chemistry Quality of Life in Individuals with Diabetic Foot Syndrome
Endocrine, Metabolic & Immune Disorders - Drug Targets Moraceae Plants with Tyrosinase Inhibitory Activity: A Review
Mini-Reviews in Medicinal Chemistry Nucleic Acid Aptamers: Clinical Applications and Promising New Horizons
Current Medicinal Chemistry Effects of Onion Extract on Endogenous Vascular H2S and Adrenomedulin in Rat Atherosclerosis
Current Pharmaceutical Biotechnology Pancreatic β-Cells and Type 2 Diabetes Development
Current Diabetes Reviews New Insights into the Pleiotropic Effects of Statins for Stroke Prevention
Mini-Reviews in Medicinal Chemistry Innate Immunity in the Female Reproductive Tract: Role of Sex Hormones in Regulating Uterine Epithelial Cell Protection Against Pathogens
Current Women`s Health Reviews Mechanisms of Drug Induced QT Interval Prolongation
Current Drug Safety Real-World Clinical Effectiveness and Tolerability of Hydroxychloroquine 400 Mg in Uncontrolled Type 2 Diabetes Subjects who are not Willing to Initiate Insulin Therapy (HYQ-Real-World Study)
Current Diabetes Reviews Vaccination Against High Blood Pressure
Current Pharmaceutical Design Inflammation, Endothelial Dysfunction and Arterial Stiffness as Therapeutic Targets in Cardiovascular Medicine
Current Pharmaceutical Design Glucose Metabolism and Antidepressant Medication
Current Pharmaceutical Design A Randomized Controlled Trial of a Herbal Compound for Improving Metabolic Parameters in Diabetic Patients with Uncontrolled Dyslipidemia
Endocrine, Metabolic & Immune Disorders - Drug Targets Sitagliptin and Vildagliptin: Efficacy of Therapy in Type 2 Diabetes
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued)